Colchicine
- PDF / 169,894 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 98 Downloads / 161 Views
1 S
Myoneuropathy secondary to drug toxicity: case report A 56-year-old man developed myoneuropathy secondary to colchicine toxicity during treatment with colchicine for gout. The man, who had stage 5 chronic renal disease and gout, was receiving treatment with colchicine [route and dosage not stated]. He was then admitted or eveluation. He started suffering from distal numbness in all four limbs 6 months prior to admission. One month prior to presentation, he developed progressive gait instability and weakness in all extremities leading to the loss of independent walking. On admission, he was found to have proximal limb weakness with absent muscle stretch reflexes in the legs. His vibration sensation was reduced, and position sensation was abolished in all four limbs. He had a significant sensory gait ataxia. Laboratory test showed renal function deterioration with increased serum creatine kinase level on 31 July 2019. Electromyography showed signs of acute sensory-motor axonal polyneuropathy. Muscle biopsy showed intracellular vacuoles with basophilic granular material, confirming the diagnosis of vacuolar myopathy. Myoneuropathy induced by colchicine toxicity was considered [duration of treatment to reaction onset not stated]. The man’s treatment with colchicine was terminated, which resulted in a rapid progressive improvement in weakness, and his creatine kinase levels normalised in 2020. Numbness and disturbance of vibration and position sensations persisted months after discharge, which indicated that myopathic changes were shortly reversible, but the neuropathic pathology induced by colchicine persisted. Fernandez Revuelta A, et al. Myoneuropathy induced by colchicine toxicity: Divergent prognosis for myopathic and neuropathic symptoms. European Journal of Neurology 27 803498481 (Suppl. 1): 746-747 (plus poster) abstr. EPO1350, May 2020. Available from: URL: https://onlinelibrary.wiley.com/toc/14681331/2020/27/S1 [abstract]
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
